Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atopic dermatitis

Eric L Simpson1, Jon M Hanifin

  • 1Department of Dermatology, Oregon Health & Science University, Portland, Oregon 97239-3098, USA.

Journal of the American Academy of Dermatology
|June 21, 2005
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi Consensus.

Dermatitis : contact, atopic, occupational, drug·2026
Same author

Defining the Potential for Disease Modification in Atopic Dermatitis.

American journal of clinical dermatology·2026
Same author

Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammation.

Frontiers in immunology·2026
Same author

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

The Journal of dermatological treatment·2026
Same author

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.

Dermatology and therapy·2026
Same author

Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials.

The Journal of dermatological treatment·2026
Same journal

Highlights from JAAD Case Reports: September 2026: Repurposing established therapies through biologic insight.

Journal of the American Academy of Dermatology·2026
Same journal

First-Come, First-Served: Ethics of Coordinated Interview Releases.

Journal of the American Academy of Dermatology·2026
Same journal

Ethical Implications of Integrating Artificial Intelligence Tools into Dermatology Electronic Health Records.

Journal of the American Academy of Dermatology·2026
Same journal

Real-world experience with extended deucravacitinib-biologic combination therapy in refractory psoriasis and psoriatic arthritis.

Journal of the American Academy of Dermatology·2026
Same journal

Acute-phase Disease and Super-responder Status Predict Reduced Relapse Risk After Ritlecitinib Withdrawal in Alopecia Areata: A Prospective Real-World Study.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Kvist-Hansen et al. 'Baseline monocytes ≥925/μL appear to represent a rare outlier phenotype rather than a generalizable predictor of adalimumab response in hidradenitis suppurativa.'

Journal of the American Academy of Dermatology·2026
See all related articles